mRNA-4157,Pembrolizumab
Moderna,Merck
['mrna-4157', 'melanoma', 'pembro']
new phase 2 safety and efficacy data was presented at #aacr2023 on mrna-4157, a personalized cancer vaccine combined with #pembrolizumab, an anti-pd-1 therapy, as adjuvant treatment for high-risk #melanoma. 
Dermatology Times: The latest news and trends in dermatologic procedures, therapy, technology, products and drugs.